Deutivacaftor / Tezacaftor / Vanzacaftor (1) – Alyftrek®
Cystic fibrosis, at least one non-Class I mutation, aged ≥ 6 years
Characteristics
| Start date | 01.08.2025 |
|---|---|
| Resolution | 22.01.2026 |
| INN | Deutivacaftor/Tezacaftor/Vanzacaftor |
| Brand name | Alyftrek® |
| Pharm. company | Vertex Pharmaceuticals (Germany) GmbH |
| G-BA Procedure ID | D-1213 |
| Therapeutic area | Metabolic diseases Orphan |
| Reason for procedure | not completed: discontinued |
Associated procedures
<< List of all resolutions